+357 96 030922
info@marketpublishers.com

Global Subcutaneous Allergy Immunotherapies Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/G3E0EE180B61EN.html
Date: September 2026
Pages: 98
Price: US$ 4,480.00 (Single User License)
ID: G3E0EE180B61EN

Abstracts

The global Subcutaneous Allergy Immunotherapies market size is expected to reach $ 2298 million by 2032, rising at a market growth of 7.0% CAGR during the forecast period (2026-2032).

Subcutaneous Allergy Immunotherapies refer to allergen-specific immunotherapy products and treatment regimens administered through repeated subcutaneous injection of clinically relevant allergen preparations to induce progressive immune tolerance and reduce sensitivity to the causative allergen. The treatment typically begins with a dose-escalation phase followed by maintenance injections, with dosing individualized according to allergen sensitivity, treatment tolerance and clinical response. The product scope covers subcutaneous preparations based on pollen, house dust mite, animal dander, mold and insect venom allergens, including native allergen extracts and modified allergen extracts or allergoids, as well as single-allergen and multi-allergen formulations and perennial, preseasonal and pre-/co-seasonal treatment schedules. The principal clinical applications are allergic rhinitis and rhinoconjunctivitis, selected cases of allergic asthma and insect venom allergy. Unlike symptomatic allergy medications, Subcutaneous Allergy Immunotherapies act on allergen-specific immune responses and are positioned as a long-term, potentially disease-modifying therapeutic approach.

Key Findings

SCIT provides disease-modifying treatment through repeated subcutaneous allergen injections

+357 96 030922
info@marketpublishers.com

Respiratory allergy remains the core clinical application of SCIT

House dust mite and pollen are central respiratory allergen targets

Clinic-based long-term administration creates substantial patient adherence requirements

Venom immunotherapy represents a specialized established SCIT application

Market Trends

The Subcutaneous Allergy Immunotherapies market is gradually shifting from traditional extract-based treatment toward more standardized, evidence-supported and patient-specific therapeutic strategies. Product development increasingly emphasizes consistent allergen potency, improved characterization of source materials, controlled formulation and dosing protocols, and stronger clinical evidence for defined allergens and patient groups. Native allergen extracts remain important, while modified allergen preparations such as allergoids continue to provide an alternative product strategy in established markets. At the same time, treatment convenience is becoming a more important competitive factor because conventional SCIT requires repeated healthcare visits during both build-up and maintenance phases. This creates continuing pressure to optimize injection schedules, simplify patient pathways and improve adherence. Competition from sublingual immunotherapy also encourages SCIT manufacturers to reinforce differentiation through broader allergen portfolios, flexible individualized treatment, established physician experience and applications where supervised injection remains clinically relevant.

Market Dynamics

Drivers

Demand for Subcutaneous Allergy Immunotherapies is primarily supported by the persistent clinical burden of allergic rhinitis, rhinoconjunctivitis and allergic asthma, particularly among patients whose symptoms remain inadequately controlled by allergen avoidance and symptomatic medication. SCIT has an established therapeutic role because it targets the allergen-specific immune response rather than only suppressing symptoms and can provide sustained clinical benefit after an appropriately

+357 96 030922
info@marketpublishers.com

completed treatment course. Its inclusion in specialist allergy treatment pathways and its applicability across multiple inhalant allergens further support long-term demand. In addition, improvements in allergy diagnosis and identification of clinically relevant sensitization allow physicians to match patients more precisely with allergen-specific treatment, strengthening the clinical rationale for immunotherapy.

Restraints

The principal restraint is the treatment burden associated with repeated injections over an extended period. Conventional SCIT generally requires a build-up phase followed by maintenance administration, and injections must be conducted under professional medical supervision because systemic allergic reactions, including anaphylaxis, can occur. The FDA prescribing information for allergenic extracts requires post-injection observation and individualized dose adjustment, illustrating the operational intensity of this treatment model. These requirements increase the time commitment for both patients and healthcare providers and can negatively affect persistence. Meanwhile, sublingual immunotherapy provides a competing route with greater potential for home administration in suitable patients, placing additional pressure on SCIT where both routes are clinically available.

Opportunities

Market opportunities increasingly lie in improving the quality and accessibility of allergen-specific treatment rather than simply expanding the number of extract products. Better allergen standardization, stronger clinical evidence, improved dose optimization and more convenient treatment schedules can expand the number of patients able to remain on therapy. House dust mite and pollen allergy remain particularly important areas for respiratory allergy immunotherapy, while better identification of clinically relevant sensitization can support more targeted selection of single-allergen or multi-allergen regimens. Pediatric allergy care also represents a longer-term opportunity where appropriate diagnosis, safety management and treatment adherence can be established. In emerging allergy-treatment markets, expansion of specialist diagnosis and physician familiarity with immunotherapy may gradually increase the addressable patient population.

Challenges

+357 96 030922
info@marketpublishers.com

The industry faces a continuing balance between treatment efficacy, safety, standardization and individualized dosing. Allergen extracts originate from biologically variable source materials, making source control, potency consistency and batch management critical manufacturing and regulatory issues. The FDA notes that different formulations, preparations and lots of certain allergenic extracts are not automatically interchangeable, reinforcing the importance of product-specific quality control. Commercially, companies must also address patient drop-off during long treatment courses, physician capacity constraints and competition from alternative immunotherapy routes. Regulatory expectations for evidence-based allergen products are becoming increasingly important, raising development and compliance requirements while favoring suppliers with strong manufacturing, clinical and regulatory capabilities.

Industry Chain Analysis

The upstream industry chain of Subcutaneous Allergy Immunotherapies begins with biological allergen source materials, including pollen, house dust mites, animal-derived materials, molds and insect venom. These materials require controlled sourcing or cultivation, identification, extraction and purification before being formulated into allergenic preparations. Manufacturing quality depends heavily on allergen characterization, biological potency, stability and consistency because the active ingredients are biologically complex rather than conventional small molecules. Formulation may involve native extracts or chemically modified allergen preparations, together with suitable diluents and, depending on the product system, depot or adjuvant technologies. Standardization and quality control therefore account for a significant part of technical value creation.

The midstream consists of specialized allergy immunotherapy manufacturers responsible for extraction, formulation, filling, quality testing, clinical development, regulatory registration and product supply. Downstream treatment is concentrated in allergy clinics, hospital allergy departments and other specialist medical settings capable of patient diagnosis, allergen selection, dose escalation and adverse-reaction management. The overall value chain is therefore closely connected to physician expertise: product value is created not only through manufacturing but also through accurate identification of the clinically relevant allergen, selection of an appropriate regimen, individualized dosing and long-term patient management. This combination of biological manufacturing complexity and specialist clinical delivery creates meaningful barriers to entry.

+357 96 030922
info@marketpublishers.com

Segment Insights

By allergen source, the Subcutaneous Allergy Immunotherapies portfolio can be divided into pollen, house dust mite, animal dander, mold and insect venom immunotherapy. Pollen and house dust mite products are central to respiratory allergy treatment because they address common triggers of allergic rhinitis, rhinoconjunctivitis and allergic asthma. Animal dander and mold products broaden the respiratory allergen portfolio, while insect venom immunotherapy forms a clinically distinct segment focused on prevention of recurrent systemic reactions following stings. Consequently, product attractiveness depends not only on allergen prevalence but also on the ability to establish a clear relationship between sensitization, clinical symptoms and patient eligibility for long-term immunotherapy.

By preparation, native allergen extracts and modified allergen extracts or allergoids represent different approaches to allergen formulation. Treatment can further be differentiated into perennial, preseasonal and pre-/co-seasonal schedules, reflecting differences in allergen exposure patterns, particularly for seasonal pollen allergies. Single-allergen SCIT enables focused treatment of a clearly identified sensitization, whereas multi-allergen SCIT provides greater flexibility for appropriately selected polysensitized patients. These segment structures indicate that the market is not moving toward a single universal formulation; instead, regional treatment practices, allergen epidemiology, product regulation and physician preferences continue to support multiple therapeutic configurations.

Downstream Market Opportunities

Allergic rhinitis and rhinoconjunctivitis represent the broadest recurring clinical opportunity for Subcutaneous Allergy Immunotherapies because patients frequently experience persistent or seasonal symptoms linked to identifiable inhalant allergens. Selected patients with allergic asthma provide an additional opportunity where allergen exposure is clinically relevant and asthma is sufficiently controlled for immunotherapy to be considered safely. Insect venom allergy represents a smaller but highly specialized application in which immunotherapy is used to reduce the risk of subsequent moderate-to-severe systemic sting reactions. Future downstream expansion will depend increasingly on earlier allergy diagnosis, more accurate identification of causative allergens, improved referral from primary care to allergy specialists and better treatment persistence rather than indiscriminate expansion of eligible populations.

+357 96 030922
info@marketpublishers.com

Regional Insights

Europe represents one of the most established regions for allergen immunotherapy, supported by long-standing specialist use, broad manufacturer participation and multiple product concepts including conventional native extracts and modified allergen preparations. The region is also experiencing a gradual transition toward more standardized and evidence-supported allergen immunotherapy products. North America has a distinctive SCIT model in which allergenic extract concentrates and individualized treatment preparations play an important role in physician-based allergy practices, making extract quality, mixing protocols and individualized dose management central to the market structure.

China represents an important growth opportunity for Subcutaneous Allergy Immunotherapies, particularly in house dust mite allergy. ALK has identified China as an important market for house dust mite immunotherapy and reported renewed SCIT shipment growth to China in 2026, providing evidence that injection-based treatment continues to maintain commercial relevance despite the development of sublingual alternatives. Across other Asian markets, expansion will depend on specialist access, regulatory pathways, local allergen profiles and physician acceptance. Regional market development is therefore likely to remain heterogeneous rather than converge rapidly toward a single administration model.

Report Scope

This report studies the global Subcutaneous Allergy Immunotherapies demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Subcutaneous Allergy Immunotherapies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Subcutaneous Allergy Immunotherapies that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Subcutaneous Allergy Immunotherapies total market, 2021-2032, (USD Million)

+357 96 030922
info@marketpublishers.com

Global Subcutaneous Allergy Immunotherapies total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Subcutaneous Allergy Immunotherapies total market, key domestic companies, and share, (USD Million)

Global Subcutaneous Allergy Immunotherapies revenue by player, revenue and market share 2021-2026, (USD Million)

Global Subcutaneous Allergy Immunotherapies total market by Type, CAGR, 2021-2032, (USD Million)

Global Subcutaneous Allergy Immunotherapies total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Subcutaneous Allergy Immunotherapies market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ALK-Abello, Stallergenes Greer, Merck, Allergy Therapeutics, HAL, Holister Stier, Leti, Torii Pharmaceutical, Lofarma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Subcutaneous Allergy Immunotherapies market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Subcutaneous Allergy Immunotherapies Market, By Region:

+357 96 030922
info@marketpublishers.com

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global Subcutaneous Allergy Immunotherapies Market, Segmentation by Type:

Perennial SCIT

Seasonal SCIT

Global Subcutaneous Allergy Immunotherapies Market, Segmentation by Allergen Source:

Pollen Allergen Immunotherapy

House Dust Mite Allergen Immunotherapy

Animal Dander Allergen Immunotherapy

Mold Allergen Immunotherapy

+357 96 030922
info@marketpublishers.com

Insect Venom Immunotherapy

Global Subcutaneous Allergy Immunotherapies Market, Segmentation by Allergen Preparation:

Single-Allergen Immunotherapy

Mixed-Allergen Immunotherapy

Global Subcutaneous Allergy Immunotherapies Market, Segmentation by Application:

Allergic Rhinitis

Allergic Asthma

Others

Companies Profiled:

ALK-Abello

Stallergenes Greer

Merck

Allergy Therapeutics

HAL

Holister Stier

Leti

Torii Pharmaceutical

+357 96 030922
info@marketpublishers.com

Lofarma

Key Questions Answered

1. How big is the global Subcutaneous Allergy Immunotherapies market?
2. What is the demand of the global Subcutaneous Allergy Immunotherapies market?
3. What is the year over year growth of the global Subcutaneous Allergy Immunotherapies market?
4. What is the total value of the global Subcutaneous Allergy Immunotherapies market?
5. Who are the Major Players in the global Subcutaneous Allergy Immunotherapies market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 Subcutaneous Allergy Immunotherapies Introduction
1.2 World Subcutaneous Allergy Immunotherapies Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Subcutaneous Allergy Immunotherapies Total Market by Region (by Headquarter Location)
  1.3.1 World Subcutaneous Allergy Immunotherapies Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032)
  1.3.3 China Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032)
  1.3.4 Europe Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032)
  1.3.5 Japan Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032)
  1.3.6 South Korea Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032)
  1.3.7 ASEAN Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032)
  1.3.8 India Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Subcutaneous Allergy Immunotherapies Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032)
2.2 World Subcutaneous Allergy Immunotherapies Consumption Value by Region
  2.2.1 World Subcutaneous Allergy Immunotherapies Consumption Value by Region (2021-2026)
  2.2.2 World Subcutaneous Allergy Immunotherapies Consumption Value Forecast by Region (2027-2032)
2.3 United States Subcutaneous Allergy Immunotherapies Consumption Value

+357 96 030922
info@marketpublishers.com

(2021-2032)
2.4 China Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032)
2.5 Europe Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032)
2.6 Japan Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032)
2.7 South Korea Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032)
2.8 ASEAN Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032)
2.9 India Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032)

3 WORLD SUBCUTANEOUS ALLERGY IMMUNOTHERAPIES COMPANIES COMPETITIVE ANALYSIS

3.1 World Subcutaneous Allergy Immunotherapies Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
  3.2.1 Global Subcutaneous Allergy Immunotherapies Industry Rank of Major Players
  3.2.2 Global Concentration Ratios (CR4) for Subcutaneous Allergy Immunotherapies in 2025
  3.2.3 Global Concentration Ratios (CR8) for Subcutaneous Allergy Immunotherapies in 2025
3.3 Subcutaneous Allergy Immunotherapies Company Evaluation Quadrant
3.4 Subcutaneous Allergy Immunotherapies Market: Overall Company Footprint Analysis
  3.4.1 Subcutaneous Allergy Immunotherapies Market: Region Footprint
  3.4.2 Subcutaneous Allergy Immunotherapies Market: Company Product Type Footprint
  3.4.3 Subcutaneous Allergy Immunotherapies Market: Company Product Application Footprint
3.5 Competitive Environment
  3.5.1 Historical Structure of the Industry
  3.5.2 Barriers of Market Entry
  3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Subcutaneous Allergy Immunotherapies Revenue Comparison (by Headquarter Location)
  4.1.1 United States VS China: Subcutaneous Allergy Immunotherapies Revenue

+357 96 030922
info@marketpublishers.com

Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Subcutaneous Allergy Immunotherapies Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Subcutaneous Allergy Immunotherapies Consumption Value Comparison
4.2.1 United States VS China: Subcutaneous Allergy Immunotherapies Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Subcutaneous Allergy Immunotherapies Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Subcutaneous Allergy Immunotherapies Companies and Market Share, 2021-2026
4.3.1 United States Based Subcutaneous Allergy Immunotherapies Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Subcutaneous Allergy Immunotherapies Revenue, (2021-2026)
4.4 China Based Companies Subcutaneous Allergy Immunotherapies Revenue and Market Share, 2021-2026
4.4.1 China Based Subcutaneous Allergy Immunotherapies Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Subcutaneous Allergy Immunotherapies Revenue, (2021-2026)
4.5 Rest of World Based Subcutaneous Allergy Immunotherapies Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Subcutaneous Allergy Immunotherapies Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Subcutaneous Allergy Immunotherapies Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Subcutaneous Allergy Immunotherapies Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Perennial SCIT
5.2.2 Seasonal SCIT
5.3 Market Segment by Type
5.3.1 World Subcutaneous Allergy Immunotherapies Market Size by Type (2021-2026)
5.3.2 World Subcutaneous Allergy Immunotherapies Market Size by Type (2027-2032)
5.3.3 World Subcutaneous Allergy Immunotherapies Market Size Market Share by

+357 96 030922
info@marketpublishers.com

Type (2027-2032)

6 MARKET ANALYSIS BY ALLERGEN SOURCE

6.1 World Subcutaneous Allergy Immunotherapies Market Size Overview by Allergen Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Allergen Source
  6.2.1 Pollen Allergen Immunotherapy
  6.2.2 House Dust Mite Allergen Immunotherapy
  6.2.3 Animal Dander Allergen Immunotherapy
  6.2.4 Mold Allergen Immunotherapy
  6.2.5 Insect Venom Immunotherapy
6.3 Market Segment by Allergen Source
  6.3.1 World Subcutaneous Allergy Immunotherapies Market Size by Allergen Source (2021-2026)
  6.3.2 World Subcutaneous Allergy Immunotherapies Market Size by Allergen Source (2027-2032)
  6.3.3 World Subcutaneous Allergy Immunotherapies Market Size Market Share by Allergen Source (2027-2032)

7 MARKET ANALYSIS BY ALLERGEN PREPARATION

7.1 World Subcutaneous Allergy Immunotherapies Market Size Overview by Allergen Preparation: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Allergen Preparation
  7.2.1 Single-Allergen Immunotherapy
  7.2.2 Mixed-Allergen Immunotherapy
7.3 Market Segment by Allergen Preparation
  7.3.1 World Subcutaneous Allergy Immunotherapies Market Size by Allergen Preparation (2021-2026)
  7.3.2 World Subcutaneous Allergy Immunotherapies Market Size by Allergen Preparation (2027-2032)
  7.3.3 World Subcutaneous Allergy Immunotherapies Market Size Market Share by Allergen Preparation (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Subcutaneous Allergy Immunotherapies Market Size Overview by Application: 2021 VS 2025 VS 2032

+357 96 030922
info@marketpublishers.com

8.2 Segment Introduction by Application
8.2.1 Allergic Rhinitis
8.2.2 Allergic Asthma
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Subcutaneous Allergy Immunotherapies Market Size by Application (2021-2026)
8.3.2 World Subcutaneous Allergy Immunotherapies Market Size by Application (2027-2032)
8.3.3 World Subcutaneous Allergy Immunotherapies Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 ALK-Abello
9.1.1 ALK-Abello Details
9.1.2 ALK-Abello Major Business
9.1.3 ALK-Abello Subcutaneous Allergy Immunotherapies Product and Services
9.1.4 ALK-Abello Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 ALK-Abello Recent Developments/Updates
9.1.6 ALK-Abello Competitive Strengths & Weaknesses
9.2 Stallergenes Greer
9.2.1 Stallergenes Greer Details
9.2.2 Stallergenes Greer Major Business
9.2.3 Stallergenes Greer Subcutaneous Allergy Immunotherapies Product and Services
9.2.4 Stallergenes Greer Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Stallergenes Greer Recent Developments/Updates
9.2.6 Stallergenes Greer Competitive Strengths & Weaknesses
9.3 Merck
9.3.1 Merck Details
9.3.2 Merck Major Business
9.3.3 Merck Subcutaneous Allergy Immunotherapies Product and Services
9.3.4 Merck Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Merck Recent Developments/Updates
9.3.6 Merck Competitive Strengths & Weaknesses

+357 96 030922
info@marketpublishers.com

9.4 Allergy Therapeutics
9.4.1 Allergy Therapeutics Details
9.4.2 Allergy Therapeutics Major Business
9.4.3 Allergy Therapeutics Subcutaneous Allergy Immunotherapies Product and Services
9.4.4 Allergy Therapeutics Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Allergy Therapeutics Recent Developments/Updates
9.4.6 Allergy Therapeutics Competitive Strengths & Weaknesses
9.5 HAL
9.5.1 HAL Details
9.5.2 HAL Major Business
9.5.3 HAL Subcutaneous Allergy Immunotherapies Product and Services
9.5.4 HAL Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 HAL Recent Developments/Updates
9.5.6 HAL Competitive Strengths & Weaknesses
9.6 Holister Stier
9.6.1 Holister Stier Details
9.6.2 Holister Stier Major Business
9.6.3 Holister Stier Subcutaneous Allergy Immunotherapies Product and Services
9.6.4 Holister Stier Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Holister Stier Recent Developments/Updates
9.6.6 Holister Stier Competitive Strengths & Weaknesses
9.7 Leti
9.7.1 Leti Details
9.7.2 Leti Major Business
9.7.3 Leti Subcutaneous Allergy Immunotherapies Product and Services
9.7.4 Leti Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Leti Recent Developments/Updates
9.7.6 Leti Competitive Strengths & Weaknesses
9.8 Torii Pharmaceutical
9.8.1 Torii Pharmaceutical Details
9.8.2 Torii Pharmaceutical Major Business
9.8.3 Torii Pharmaceutical Subcutaneous Allergy Immunotherapies Product and Services
9.8.4 Torii Pharmaceutical Subcutaneous Allergy Immunotherapies Revenue, Gross

+357 96 030922
info@marketpublishers.com

Margin and Market Share (2021-2026)
9.8.5 Torii Pharmaceutical Recent Developments/Updates
9.8.6 Torii Pharmaceutical Competitive Strengths & Weaknesses
9.9 Lofarma
9.9.1 Lofarma Details
9.9.2 Lofarma Major Business
9.9.3 Lofarma Subcutaneous Allergy Immunotherapies Product and Services
9.9.4 Lofarma Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Lofarma Recent Developments/Updates
9.9.6 Lofarma Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 Subcutaneous Allergy Immunotherapies Industry Chain
10.2 Subcutaneous Allergy Immunotherapies Upstream Analysis
10.3 Subcutaneous Allergy Immunotherapies Midstream Analysis
10.4 Subcutaneous Allergy Immunotherapies Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World Subcutaneous Allergy Immunotherapies Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Subcutaneous Allergy Immunotherapies Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Subcutaneous Allergy Immunotherapies Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Subcutaneous Allergy Immunotherapies Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Subcutaneous Allergy Immunotherapies Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Subcutaneous Allergy Immunotherapies Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Subcutaneous Allergy Immunotherapies Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Subcutaneous Allergy Immunotherapies Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Subcutaneous Allergy Immunotherapies Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Subcutaneous Allergy Immunotherapies Players in 2025
Table 12. World Subcutaneous Allergy Immunotherapies Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Subcutaneous Allergy Immunotherapies Company Evaluation Quadrant
Table 14. Head Office of Key Subcutaneous Allergy Immunotherapies Players
Table 15. Subcutaneous Allergy Immunotherapies Market: Company Product Type Footprint
Table 16. Subcutaneous Allergy Immunotherapies Market: Company Product Application Footprint
Table 17. Subcutaneous Allergy Immunotherapies Mergers & Acquisitions Activity
Table 18. United States VS China Subcutaneous Allergy Immunotherapies Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Subcutaneous Allergy Immunotherapies Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

+357 96 030922
info@marketpublishers.com

Table 20. United States Based Subcutaneous Allergy Immunotherapies Companies, Headquarters (States, Country)
Table 21. United States Based Companies Subcutaneous Allergy Immunotherapies Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Subcutaneous Allergy Immunotherapies Revenue Market Share (2021-2026)
Table 23. China Based Subcutaneous Allergy Immunotherapies Companies, Headquarters (Province, Country)
Table 24. China Based Companies Subcutaneous Allergy Immunotherapies Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Subcutaneous Allergy Immunotherapies Revenue Market Share (2021-2026)
Table 26. Rest of World Based Subcutaneous Allergy Immunotherapies Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Subcutaneous Allergy Immunotherapies Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Subcutaneous Allergy Immunotherapies Revenue Market Share (2021-2026)
Table 29. World Subcutaneous Allergy Immunotherapies Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Subcutaneous Allergy Immunotherapies Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Subcutaneous Allergy Immunotherapies Market Size by Type (2027-2032) & (USD Million)
Table 32. World Subcutaneous Allergy Immunotherapies Market Size by Allergen Source, (USD Million), 2021 & 2025 & 2032
Table 33. World Subcutaneous Allergy Immunotherapies Market Size Value by Allergen Source (2021-2026) & (USD Million)
Table 34. World Subcutaneous Allergy Immunotherapies Market Size by Allergen Source (2027-2032) & (USD Million)
Table 35. World Subcutaneous Allergy Immunotherapies Market Size by Allergen Preparation, (USD Million), 2021 & 2025 & 2032
Table 36. World Subcutaneous Allergy Immunotherapies Market Size Value by Allergen Preparation (2021-2026) & (USD Million)
Table 37. World Subcutaneous Allergy Immunotherapies Market Size by Allergen Preparation (2027-2032) & (USD Million)
Table 38. World Subcutaneous Allergy Immunotherapies Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Subcutaneous Allergy Immunotherapies Market Size by Application

+357 96 030922
info@marketpublishers.com

(2021-2026) & (USD Million)
Table 40. World Subcutaneous Allergy Immunotherapies Market Size by Application (2027-2032) & (USD Million)
Table 41. ALK-Abello Basic Information, Manufacturing Base and Competitors
Table 42. ALK-Abello Major Business
Table 43. ALK-Abello Subcutaneous Allergy Immunotherapies Product and Services
Table 44. ALK-Abello Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. ALK-Abello Recent Developments/Updates
Table 46. ALK-Abello Competitive Strengths & Weaknesses
Table 47. Stallergenes Greer Basic Information, Manufacturing Base and Competitors
Table 48. Stallergenes Greer Major Business
Table 49. Stallergenes Greer Subcutaneous Allergy Immunotherapies Product and Services
Table 50. Stallergenes Greer Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Stallergenes Greer Recent Developments/Updates
Table 52. Stallergenes Greer Competitive Strengths & Weaknesses
Table 53. Merck Basic Information, Manufacturing Base and Competitors
Table 54. Merck Major Business
Table 55. Merck Subcutaneous Allergy Immunotherapies Product and Services
Table 56. Merck Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Merck Recent Developments/Updates
Table 58. Merck Competitive Strengths & Weaknesses
Table 59. Allergy Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. Allergy Therapeutics Major Business
Table 61. Allergy Therapeutics Subcutaneous Allergy Immunotherapies Product and Services
Table 62. Allergy Therapeutics Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Allergy Therapeutics Recent Developments/Updates
Table 64. Allergy Therapeutics Competitive Strengths & Weaknesses
Table 65. HAL Basic Information, Manufacturing Base and Competitors
Table 66. HAL Major Business
Table 67. HAL Subcutaneous Allergy Immunotherapies Product and Services
Table 68. HAL Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. HAL Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

Table 70. HAL Competitive Strengths & Weaknesses
Table 71. Holister Stier Basic Information, Manufacturing Base and Competitors
Table 72. Holister Stier Major Business
Table 73. Holister Stier Subcutaneous Allergy Immunotherapies Product and Services
Table 74. Holister Stier Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Holister Stier Recent Developments/Updates
Table 76. Holister Stier Competitive Strengths & Weaknesses
Table 77. Leti Basic Information, Manufacturing Base and Competitors
Table 78. Leti Major Business
Table 79. Leti Subcutaneous Allergy Immunotherapies Product and Services
Table 80. Leti Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Leti Recent Developments/Updates
Table 82. Leti Competitive Strengths & Weaknesses
Table 83. Torii Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 84. Torii Pharmaceutical Major Business
Table 85. Torii Pharmaceutical Subcutaneous Allergy Immunotherapies Product and Services
Table 86. Torii Pharmaceutical Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Torii Pharmaceutical Recent Developments/Updates
Table 88. Torii Pharmaceutical Competitive Strengths & Weaknesses
Table 89. Lofarma Basic Information, Manufacturing Base and Competitors
Table 90. Lofarma Major Business
Table 91. Lofarma Subcutaneous Allergy Immunotherapies Product and Services
Table 92. Lofarma Subcutaneous Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Lofarma Recent Developments/Updates
Table 94. Lofarma Competitive Strengths & Weaknesses
Table 95. Global Key Players of Subcutaneous Allergy Immunotherapies Upstream (Raw Materials)
Table 96. Global Subcutaneous Allergy Immunotherapies Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Subcutaneous Allergy Immunotherapies Picture
Figure 2. World Subcutaneous Allergy Immunotherapies Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Subcutaneous Allergy Immunotherapies Total Revenue (2021-2032) & (USD Million)
Figure 4. World Subcutaneous Allergy Immunotherapies Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Subcutaneous Allergy Immunotherapies Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Subcutaneous Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 13. Subcutaneous Allergy Immunotherapies Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 16. World Subcutaneous Allergy Immunotherapies Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 18. China Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)

+357 96 030922
info@marketpublishers.com

Figure 20. Japan Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 23. India Subcutaneous Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Subcutaneous Allergy Immunotherapies by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Subcutaneous Allergy Immunotherapies Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Subcutaneous Allergy Immunotherapies Markets in 2025
Figure 27. United States VS China: Subcutaneous Allergy Immunotherapies Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Subcutaneous Allergy Immunotherapies Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Subcutaneous Allergy Immunotherapies Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Subcutaneous Allergy Immunotherapies Market Size Market Share by Type in 2025
Figure 31. Perennial SCIT
Figure 32. Seasonal SCIT
Figure 33. World Subcutaneous Allergy Immunotherapies Market Size Market Share by Type (2021-2032)
Figure 34. World Subcutaneous Allergy Immunotherapies Market Size by Allergen Source, (USD Million), 2021 & 2025 & 2032
Figure 35. World Subcutaneous Allergy Immunotherapies Market Size Market Share by Allergen Source in 2025
Figure 36. Pollen Allergen Immunotherapy
Figure 37. House Dust Mite Allergen Immunotherapy
Figure 38. Animal Dander Allergen Immunotherapy
Figure 39. Mold Allergen Immunotherapy
Figure 40. Insect Venom Immunotherapy
Figure 41. World Subcutaneous Allergy Immunotherapies Market Size Market Share by Allergen Source (2021-2032)
Figure 42. World Subcutaneous Allergy Immunotherapies Market Size by Allergen Preparation, (USD Million), 2021 & 2025 & 2032

+357 96 030922
info@marketpublishers.com

Figure 43. World Subcutaneous Allergy Immunotherapies Market Size Market Share by Allergen Preparation in 2025
Figure 44. Single-Allergen Immunotherapy
Figure 45. Mixed-Allergen Immunotherapy
Figure 46. World Subcutaneous Allergy Immunotherapies Market Size Market Share by Allergen Preparation (2021-2032)
Figure 47. World Subcutaneous Allergy Immunotherapies Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 48. World Subcutaneous Allergy Immunotherapies Market Size Market Share by Application in 2025
Figure 49. Allergic Rhinitis
Figure 50. Allergic Asthma
Figure 51. Others
Figure 52. World Subcutaneous Allergy Immunotherapies Market Size Market Share by Application (2021-2032)
Figure 53. Subcutaneous Allergy Immunotherapies Industrial Chain
Figure 54. Methodology
Figure 55. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Subcutaneous Allergy Immunotherapies Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/G3E0EE180B61EN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G3E0EE180B61EN.html